Background. The use of cyclosporine A (CsA) as a potent immunosuppressant has been limited by its severe nephrotoxic effects. The mechanisms involved are haemodynamic but also related to direct toxic effects of CsA on proximal tubule epithelial cells. We focused on defining a proteomic profile in CsA-treated proximal tubule cells to distinguish the direct impact of CsA on these cells from overlapping haemodynamically mediated phenomena that occur in an in vivo system.
Introduction
Since its introduction in the 1980s as an immunosuppressive agent, cyclosporine A (CsA) has been widely used to prevent allograft rejection, dramatically improving outcome after organ transplantation [1] [2] [3] . Despite being highly efficacious as an immunosuppressant, and for the treatment of autoimmune diseases [4] [5] [6] , the use of CsA is limited by its associated severe nephrotoxic effects [7] . Mechanisms of CsA-induced nephrotoxicity were previously thought to be haemodynamic in origin, due to an imbalance of vasoconstrictors and vasodilators [8] . However, clinical and experimental studies have provided accumulated evidence for a direct effect of CsA on proximal tubule epithelial cells [9] [10] [11] [12] . While renal vasoconstriction is a characteristic of acute CsA toxicity and is largely reversible upon dose reduction [13] , an irreversible decline in kidney function that is associated with structural changes may also be observed after long-term CsA use [14] . Many investigations have been conducted to understand the cell-type specific mechanisms of CsA toxicity [15] . An increased rate of tubular cell apoptosis has been described in human renal biopsy specimens [16] , and several groups have shown that CsA induces apoptosis and necrosis in tubular cells in a dose-and time-dependent manner [17] [18] [19] [20] . The involvement of reactive oxygen species (ROS) as a causative factor in cell damage has been suggested [21] [22] [23] and related to the PI3K and ERK signalling pathways [24] . Recently, Sarró et al. described that inhibition of the PI3K pathway protects CsA-triggered cell death and that the pro-survival effects of PI3K inhibitors are not due to a decrease in ROS levels [25] . One of the unifying effects of CsA in cell cultures of most renal cell lines is a reduction in proliferation capacity [26] [27] [28] . A recent contribution from Jennings et al. showed that a decrease in proliferation by CsA in renal tubular epithelial cells involves distinct senescence pathways leading to accelerated ageing of renal cells [29] .
The mechanisms of chronic CsA nephrotoxicity might not necessarily relate to calcineurin inhibition, as does its immunosuppressive action [30] . CsA inhibits peptidylprolyl cis-trans isomerase activity (PPIase) of cyclophilins, which were first identified as the intracellular receptors of CsA [31, 32] . Cyclophilins have a global role in the folding of nascent proteins in vivo and also regulate the function of mature proteins by catalyzing isomerization between alternative structures contributing to conformational stability, or sterically blocking interactions between factors [33] [34] [35] [36] . PPIase activity inhibition by CsA must have an impact on specific putative downstream targets of CsA that, being essential for cell homeostasis, could be disturbed by the immunosuppressant, thereby contributing to cell dysfunction and, eventually, death. Accordingly, we propose that an accurate differential proteomic analysis between CsA-treated and non-treated cells would be useful to identify putative CsA targets that might be crucial to understand, at least in part, renal function impairment due to this calcineurin inhibitor.
Materials and methods

Cell culture
The cloned mouse renal proximal PKSV-PCT and PKSV-PR cell lines, referred to as PCT3 and PR10, respectively, have been previously described [37] . HK-2 cells, an immortalized proximal tubular epithelial cell line from adult human kidney, were purchased from American Type Culture Collection (ATCC no. CRL-2190; Manassas, VA, USA). Mouse and human proximal tubule-derived cell lines were routinely cultured as previously reported [38, 39] . HeLa cells, an epithelial cell line derived from human cervix adenocarcinoma, were obtained from ATCC and cultured in Dulbecco's Modified Eagle's Medium (DMEM) with glutamax TM (L-alanyl-L-glutamine), supplemented with 10% fetal calf serum (Gibco-Invitrogen, Paisley, UK), non-essential aminoacids, penicillin G (100 U/ml) and streptomycin (100 µg/ml) (Biological Industries, Israel).
Experimental design
Cells were trypsinized and seeded onto 96-well plates (TPP, Switzerland, Europe), 24-well plates or 6-cm plates (Iwaki, Japan) depending on the experiment. The cells were grown to near confluence for 15-18 h before treatment. CsA (Calbiochem, Merck Biosciences, Germany, Europe) was diluted in 100% ethanol at a concentration of 10 mg/ml. Further dilutions were made with culture medium. We verified for each concentration and time that the ethanol used had no effect on cell viability.
Assays
Cell viability. After CsA treatment, cell viability was determined by XTT assay (Cell Proliferation Kit II Roche, Germany, Europe) following the manufacturer's instructions. The assay is based on the cleavage of the XTT to form a formazan dye by metabolic active cells. This conversion only occurs in viable cells. The cell viability was calculated as follows: % cell viability = (Average absorbance of experimental wells/Average absorbance of control wells) × 100. At least three independent experiments were made, and each sample was tested in triplicate.
Cell death. Apoptosis was determined by the release of mono-and oligonucleosomes from the nucleus to the cytosol. The enrichment of mono-and oligonucleosomes in the cytoplasmatic fractions was analysed by the Cell Death Detection ELISA PLUS kit (Roche, German Europe) following the manufacturer's instructions. The relative degree of apoptosis was quantitatively determined by measuring the peroxidase activity at 405 nm. The absorbance ratio between the enzyme activity of treated cells and the corresponding control cells represents the enrichment factor. At least three independent experiments were made, and each sample was tested in triplicate.
Flow cytometry A total of 6.6 × 10 5 cells (PCT3 or HK-2) were seeded in 6-cm plates (Iwaki). After 15 h, the cells were treated with 10 µM of CsA for 24 h. Cell suspensions were pelleted, resuspended in 2 ml of PBS-10 mM EDTA and fixed for at least 1 h in 1 ml of 70% ice-cold ethanol at −20 • C. The cells were washed twice with PBS-1% BSA, resuspended in 1 ml PBS-1% BSA containing 250 µg/ml RNAse A (Sigma-Aldrich, Spain, Europe) and incubated at 37 • C for 1 h. After that, 30 µg/ml propidium iodide (PI) was added and the cells were guarded from light and incubated at 37 • C for 1 h. Analysis was carried out by a FacsCalibur Flow Cytometer (Beckton Dickinson, NJ, USA) with laser excitation at 488 nm using a 633-nm band pass filter to collect the PI fluorescence. Cell clumps were excluded from analysis. The percentages of the cells in the various phases of the cell cycle, namely G 0 /G 1 , S and G 2 /M, were assessed using the CellQuest Pro software (Beckton Dickinson, NJ, USA). At least three independent experiments were made, and each sample was tested in triplicate.
Differential proteomic analysis
Sample preparation and two-dimensional electrophoresis (2DE): 6.6 × 10 5 cells (PCT3 or HK-2) were seeded in 6-cm plates (Iwaki, Japan). After 18 h, the cells were treated with different doses of CsA for 24 h. The cells were washed with a Tris-sorbitol solution (10 mM and 250 mM, respectively, pH 7.4) and homogenated in 150 µl of a lysis solution (8 M urea, 4% CHAPs and 40 mM Tris). Protein concentration was determined using the bicinchoninic acid method (BCA, Pierce, Rockhard, IL, USA). Fifty micrograms of protein was mixed with a rehydration solution (8 M urea, 2% CHAPS, 0.28% DTT, 0.5% IPG ampholine buffer pH 3-10 and 0.002% bromophenol blue) and separated by isoelectric focusing in a 24-cm polyacrylamide gel with immobilized 3-10 pH gradient (Immobiline DryStrip 3-10 l, IPGphor system, Amersham Biosciences Europe, Freiburg, Germany). Gel strips with the focused proteins were equilibrated for 15 min with 10 ml of reducing SDS buffer (50 mM Tris, 6 M urea, 30% glycerol, 2% SDS, 1% DTT, 0.002% bromophenol blue) and for 15 min more with 10 ml of alkalyting SDS buffer (same buffer with 4% iodoacetamide instead of DTT). The strips were placed on a 1 mm, 16 × 24 cm SDS-PAGE gel (12.5% T, 2.6% C), and the second dimension was run for 4.5 h at 100 W in an Ettan Dalt six electrophoresis system (Amersham Biosciences Europe, Freiburg, Germany) using the Laemmli buffer. Gels were fixed in 40% ethanol/10% acetic acid, and stained with carbonate silver.
Control and 10 mM CsA-treated PCT3 cells, cultured in three independent batches, were pooled and analysed by 2DE as described above. This procedure was repeated three times in different days until obtaining three control and three CsA-treated gels, each of them consisting of three independent cell batches.
Differential analysis
Gels were scanned with a calibrated densitometer (GS800 Bio-Rad, Hercules, CA, USA) and analysed using the PDQuest R 6.2 software (Bio-Rad, Hercules, CA, USA). The software automatically analysed the independent triplicate gels of both control and CsA-treated cells. Spot assignation was checked and validated individually by visual inspection; incorrectly assigned spots (specks, streaks, bubbles, etc.) were eliminated. Individual spot intensity was normalized against the sum of intensity of the detected spots. The gels were matched and grouped. The PDQuest software performed an automatic differential analysis of the spot intensities, grouping gels by treatment, and using statistical criteria (Student's t-test) to detect differentially expressed spots. Those selected by the software as differential were checked individually by visual inspection in all gels to verify the software assignations. Validated spots were selected for MS analysis.
Protein identification by mass spectrometry
Two-dimensional gels were prepared as described above but with higher protein load (150 µg of protein per gel). The gels were stained for MS analysis with modified, glutaraldehyde-free carbonate silver staining. Differential spots were excised and digested with trypsin. Protein identification was carried out by peptide mass fingerprinting in a MALDI TOF/TOF mass spectrometer (Ultraflex TOF/TOF, Brucker Daltonics, MA, USA). MASCOT TM software (Matrix Science, MA, USA) was used for peptide mass fingerprinting.
Bioinformatic analyses
The differential proteins found were classified according the Gene Ontology hierarchies (GO) [40] . Two bioinformatics tools were used to relate and group the differential proteins, with the aim of identifying the metabolic processes and pathways altered by the treatment with CsA: FatiGO [41] and MAPPfinder [42] .
Animals and CsA treatment
Seven-week-old male C57BL/6 mice were purchased from IFFA CREDO (L'Arbescle, France, Europe). The mice were housed in the animal facilities in covered cages at 22 
Western blot analysis
Whole kidney tissues from control (n = 8) and CsA-treated (n = 8) mice were homogenized in a lysis buffer (40 mM Tris-HCl, 4% CHAPS, 8 M Urea). Protein extracts from cells and kidneys (20 µg or 60 µg, respectively) were subjected to 12% SDS-PAGE. Proteins were then transferred to a PVDF membrane (Schleicher & Schuell, Dassel, Germany, Europe) and incubated with mouse monoclonal anti-RACK-1 (1:500: Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal anti-alpha-B-crystallin (1:500; Acris Antibodies, Herford, Germany), mouse polyclonal anti-NACA (1:1000; Abnova Corporation, Taiwan), rabbit polyclonal anti-cyclophilin A (1:2000; Upstate Biotechnology, NY, USA), rabbit anti-actin (1:1000; Sigma Chemical Co., St Louis, MO, USA) and rabbit anti-MAPkinase 1/2 (Erk 1/2-CT) antibodies (1 µg/ml; Upstate Biotechnology, NY, USA). After washing, membranes were incubated with appropriate horseradish peroxidase-conjugated secondary antibody (rabbit anti-mouse 1:2000, goat anti-rabbit 1:5000, DAKO), washed and developed using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Uppsala, Sweden). X-ray films were developed and scanned in a GS800-calibrated densitometer (Bio-Rad, Hercules, CA, USA) and bands quantified using the Quantity One software (Bio-Rad, Hercules, CA, USA).
Statistical analyses
Results are expressed as mean ± SEM (standard error of the mean). XTT results were analysed in a first instance by multifactor ANOVA, with CsA dose, treatment time and cell type as factors, considering the interactions among factors. A post hoc test (LSD, least-squared differences) was used to determine the global influence of individual factors. One-way ANOVA for each dose at fixed treatment times, and vice versa, was used to check the individual differences among CsA doses and time point. The cell cycle was analysed with a multifactor ANOVA, at a fixed CsA dose of 10 000 nM and a time exposure of 24 h, with cycle phase and cell type as factors accounting for the interaction between them. Serum urea nitrogen and creatinine differences between CsA-treated and control mice were studied using Student's t-test.
Results
CsA-induced toxicity in different cell lines
Proximal tubule-derived cell lines PCT3/PR10 and HK-2, and the non-renal HeLa cell line were exposed to increasing doses of CsA (0-50 µM) for different time periods (24 h, 48 h, 72 h). XTT assays indicated that the dose and time of treatment affect cell viability and that both factors have a significant positive interaction, i.e. viability decreased when treatment time increased in a dose-dependent manner.
The results in Figure 1 show that after 24 h of treatment, 10 µM CsA caused a significant decrease in viability of PCT3, PR10 and HK-2 cell lines (P ≤ 0.05), which was similar to that observed at 20 µM and 50 µM (Figure 1 ). Doses higher than 10 µM significantly increased toxicity in a time-dependent manner, which was maximal at 48 h for PCT3 and KH-2, and at 72 h for PR10 cells (P ≤ 0.05) ( Figure 1 ). HeLa cells were not affected by CsA at any time or dose assayed, confirming that renal cells are more sensitive to CsA toxicity than cell lines of non-renal origin. Flow cytometry-based cell cycle analysis and death cell assays were performed to assess the nature of CsA-induced changes in the XTT values. Results shown in Figure 2A indicate that there was a significant decrease in the percentage of cells in the S phase for both cell lines (P ≤ 0.05) that correlated with an increment in cells in the G0/G1 or G2/M phases for HK-2 and PCT3 cells, respectively, in the presence of CsA (P ≤ 0.05 for the negative interaction treatment and cell type in G0/G1 phase). Cell death detection ELISA assays showed that 10 µM of CsA provoked a significant amount of cleaved DNA/histone complexes that indicated that PCT3 and HK-2 cells died by apoptosis under these conditions ( Figure 2B ). Altogether, these results suggest that CsA-induced DNA damage was halting progression through the cell cycle at either the G1/S or G2/M checkpoints. Cells that were preferentially arrested at the G0/G1 phase, such as HK-2, were less likely to die by apoptosis than cells, such as PCT3, that go through this phase of the cell cycle. As assessed by the XTT assays, HK-2 and PCT3 cell viability was equally affected after CsA treatment.
Dose-dependent proteomic profile of CsA-treated cells
According to previous analyses, 10 µM CsA is the threshold dose that induces changes in proximal tubule cell viability. To determine the CsA dose that changes the proteomic profile changes in a sensitive manner, lysates of cells under the same treatment used above were resolved by 2D gel electrophoresis and analysed as described in the Material and Methods section. The spot patterns across all gels analysed from control cells to those treated with CsA up to 1 µM were alike. Robust and consistent proteomic alterations were first observed at the 10 µM dose, correlating with changes first observed in cell viability. Figure 3 depicts representative spots that declined ( Figure 3A) or increased ( Figure 3B ) on PCT3 proteome after cells were treated with increasing doses of CsA for 24 h. Similar results were observed in HK-2 cells (not shown).
Differential protein expression in PCT3 cells after CsA treatment
Representative 2D gels of PCT3 control and PCT3 treated with 10 µM of CsA for 24 h are shown in Figure 4A and B, respectively. A total of 72 spots were differentially expressed in treated (n = 3) versus control cells (n = 3). Thirty-eight of these differentially expressed spots showed significant differences (P ≤ 0.05; Student's t-test) in the CsA-treated cells ( Figure 4C ). Of these, 66% were down-regulated and 34% up-regulated. Representative spots shown in Figure 4A -C were magnified and depicted in Figure 4D , as an example. These spots were characterized as shown in Table 1 and further classified into functional groups on the basis of cellular component, biological process and molecular function. This classification was made using the FATIGO and MAPPFinder bioinformatic programs. As depicted, the main functions affected by CsA in proximal tubule cells were related to protein metabolism (21%), response to damage (21%), cell organization and cytoskeleton (20%), energy metabolism (13%), cell cycle (11%) and nucleobase/nucleoside/nucleotidic metabolism (7%) ( Table 1) . 
Western blot assays of CsA-regulated protein expression in cultured cells and mouse kidney
To confirm the results obtained after the proteomic analyses and to further correlate them with the effects of CsA on kidney, Western blot (WB) assays were performed in CsAtreated or control PCT3 cells, as well as in kidneys of CsAor vehicle-treated mice.
Male mice treated for 14 days with CsA at 80 mg/kg/ day (i.m.) exhibited creatinine (0.667 ± 0.017 mg/dl) and BUN levels (44.2 ± 2.9 mg/dl) that were at least twice those found in vehicle-treated mice (0.347 ± 0.027 and 19.4 ± 2.0 mg/dl, respectively) (P ≤ 0.0006 for creatinine and P ≤ 0.002 for BUN) and histopathological alterations characteristic of CsA nephrotoxicity. For WB assays, specific antibodies against randomly selected proteins listed in Table 1 , such as αB-crystallin, RACK-1, NACA and CypA, were used and results normalized against actin or total MAPK (MAPKt) for protein loading control. Results shown in the left part of Figure 5A for αB-crystallin and NACA confirm those obtained from 2D gel analysis, since protein levels dropped after CsA treatment. For CypA, 10 µM was the dose that promoted major changes in protein expression upon 24 h of CsA treatment in both mouse PCT3 and human HK-2 cell lines ( Figure 5A ). Results from one-and two-dimensional (1D and 2D) WB assays may correlate in some instances, as occurred for αB-crystallin or CypA, or show no correlation as for RACK-1 ( Figure 5A and B). RACK-1 and CypA showed different isoforms on 2D gel WB assays that were not equally affected by CsA treatment. It is interesting to point out that while the immunosuppressant diminished all CypA isoforms, it only affected two minor RACK-1 isoforms that became absent after treatment ( Figure 5B, see arrows) . Contrary to what occurred for CypA, the disappearance of these minor RACK-1 isoforms did not have an impact on overall protein levels when analysed by 1D WB assays ( Figure  5A ). The apparent discrepancy between 2D and 1D proteomic analysis results might be related, at least in this case, to the analytical performance of each technique. Two dimensional gel analysis can disclose protein features that, while being significant from a pathophysiological point of view, might not be obvious when 1D gel analysis is used. Spot ID is the identification number assigned by the PD-Quest analysis software. When these antibodies were tested in kidney extracts from control or CsA-treated mice by WB 1D assays, results were similar to those found in PCT3 cells, except for CypA that remained the same in control or CsA-treated mice ( Figure 5C ).
Protein pattern comparison between human and mouse proximal tubule-derived cell models
XTT assays showed that PCT3 and HK-2 responded to CsA in a similar manner. We also observed that the mouse ( Figure 6A ) and human ( Figure 6B ) proteomic patterns looked alike. Three distant visually selected areas (1, 2 and 3) from the gels shown in Figure 6A and B and from the gels corresponding to additional independent experiments are depicted in Figure 6C . The computerized matching of both protein maps (allowing for geometric distortions) showed a near perfect match between the spots of the murine and human gels, with only three unpaired spots. To confirm this proteomic equivalence, 11 spots corresponding to differential and non-differential CsA-related proteins were excised from murine and human 2DE gels and sequenced. Computerized matching proteins in PCT3 and HK-2 were confirmed to be the same upon sequencing ( Table 2 ). The proteins listed in Table 1 corresponding to differentially expressed proteins in CsA-treated PCT3 were perfectly matched in the HK-2 gels and assessed as equally expressed after CsA treatment.
Discussion
For more than 20 years, CsA has improved survival in solidorgan transplants, but evidence has accumulated that CsA therapy plays a role in chronic renal failure [43] [44] [45] . While protocol biopsies are regularly performed in transplanted patients, histological evaluation does not provide clues to assess the magnitude of CsA-induced toxicity in the development of chronic allograft nephropathy, because although characteristics for this condition, interstitial fibrosis, tubular atrophy and arteriolar hyalinosis, are not specific for Twelve arbitrary spots on PCT3 2DE gels and their matching spots on HK-2 2DE gels were excised from the gels and analysed by MALDI TOF/TOF. In all instances, the proteins identified in the HK-2 gels were human homologous of the mouse proteins found in the PCT3 gel.
CsA nephrotoxicity since they can also be observed in advanced stages of many renal diseases. Therefore, and because monitorization of plasma CsA levels is not sufficient to prevent undesirable nephrotoxic effects, we aimed to identify molecular pathways and targets underlying CsAinduced toxicity. By means of high-throughput differential proteomic analyses and mass spectrometry techniques, we focused on the identification of proximal tubule markers that could eventually help to distinguish CsA toxicity from chronic allograft nephropathy in protocol biopsies of transplanted patients, therefore facilitating early interventions to adjust CsA doses to non-toxic therapeutic ranges.
To distinguish the direct impact of CsA on proximal tubule cells from overlapping haemodynamically mediated phenomena that occur in an in vivo system, we used proximal tubule-derived cell lines of human and mouse origin. The identification of common targets in both cell types indicates the conservation degree of CsA-induced toxicity mechanisms across species, and provides an experimental cell model to further address mechanistic questions in relation to the role of CsA in kidney pathophysiology at molecular level.
The immortalized PCT3 and PR10 cells represent valuable ex vivo cell systems for analysing hormone-specific regulation of kidney-specific gene promoters [46, 47] , functional studies [48] or CsA toxicity mechanisms [49] . HK-2 is widely used for functional proximal tubule studies, as reported [50] . For 24 h, 10 µM CsA produced identical effects on HK-2 and PCT3 cell viability, which was mainly characterized by alterations in cell cycle progression and apoptosis induction. Under these conditions, robust and consistent changes in the proteomic profile were also observed. A detailed differential proteomic analysis in PCT3 and HK-2 cells revealed the molecular species shown in Table 1 .
Cytoskeleton-related proteins such as myosin light polypeptide 6, APC-binding protein EB1, HSP25 and actin cytoplasmatic 2, which are structural components of the cytoskeleton, appear to intervene in microtubule polymerization, mitotic spindle stabilization or actin organization, and are down-regulated when cells are exposed to CsA, while F-actin capping protein alpha-2 subunit, keratin II cytoskeletal 8 and translationally controlled tumour protein (TCTP) appear up-regulated. These alterations would have an impact on cytoskeleton organization and cell cycle. It has recently been proposed that the highly abundant cytoskeletal protein keratin 8 can protect tissue from injury by serving as a phosphate 'sponge' for stress-activated kinases, thereby providing a novel non-mechanical function for intermediate filament proteins [51] . TCTP has also been implicated in important cellular processes, such as cell growth, cell cycle progression, malignant transformation and in the protection of cells against various stress conditions and apoptosis. In addition, an extracellular, cytokine-like function has been established for TCTP, and the protein has been implicated in various pathologically relevant processes [52] . It was recently demonstrated that transgenic mice overexpressing TCTP developed systemic arterial hypertension around 6 weeks after birth, which seems to have been caused by reduced Na(+),K(+)-ATPase activity and increased intracellular calcium, suggesting that inhibition of Na(+),K(+)-ATPase by overexpression of TCTP is involved in the pathogenesis of hypertension [53] . Because our results link TCTP overexpression with CsA toxicity, we hypothesized that haemodynamic changes produced by CsA could in part be mediated through this mechanism in proximal tubule cells. Nucleophosmin (NPM/B23) expression is an immediate-early gene response induced by damaged DNA [54] but also an important protein in cell cycle progression. NPM/B23 associates specifically with unduplicated centrosomes, and dissociates by CDK2/cyclin E-mediated phosphorylation. This is a crucial event for duplication of centrosomes and DNA, and both occur in a coordinated fashion; it has been demonstrated that blocking of NPM/B23 phosphorylation suppresses the initiation of centrosome duplication in vivo [55] . The two different NPM spots with opposite expression identified in our proteomic analysis (#2536 decreases and #3501 increases; see Table 1 ) might indicate a differential phosphorylation state for this protein that, in turn, could relate to impaired DNA synthesis and a lower number of cells in the S phase, as we found to occur in PCT3 and HK-2 cells (Figure 2A) . These results would also explain the lower levels of PCNA found in CsA-treated cells.
Some of our proteomic findings are in agreement with results reported by other authors when studying organspecific metabolic changes after in vivo CsA treatment. Serkova et al. found that CsA decreased the energy balance [adenosine triphosphate (ATP)/adenosine diphosphate (ADP)] in kidney as well as in heart and liver due to decreased activity of the mitochondrial Krebs cycle and oxidative phosphorylation [56] . Our analysis revealed the following alterations: (1) a decrease in electron-transfer flavoprotein alpha subunit, which accepts electrons from several dehydrogenases and transfers them to the mitochondrial respiratory chain; (2) lower levels of prohibitin (PHB), a highly conserved protein mainly localized to the inner mitochondrial membrane and, among other functions, involved in the assembly of mitochondrial respiratory chain enzymes. It was recently reported [57] that a knockdown of PHB in endothelial cells increases mitochondrial production of ROS via inhibition of complex I, which results in cellular senescence; (3) lower levels of ATP synthase D, an end-point component of the mitochondrial respiratory chain; (4) decreased levels of isocitrate dehydrogenase, a key regulator Krebs cycle enzyme; and (5) a decrease in Acetyl-CoA acetyltransferase that produces Acetyl-CoA for the Krebs cycle. Altogether, these results indicate that the oxidative aerobic pathway was shut down in our cells, which fits with other authors' results using different in vivo approaches. Serkova et al. also described an increase in anaerobic glycolysis as a compensatory effect [56] . Since pyruvate kinase levels were augmented in our analysis, it is likely that CsA induced anaerobic glycolysis in our cells.
Other proteins related to mRNA stabilization, protein synthesis, targeting to endoplasmic reticulum and folding, such as alpha-complex protein 1, eukaryotic translation initiation factor 5A, nascent polypeptide-associated complex alpha (NACA), cyclophilin A, small heat shock protein 8 and αB-crystallin appeared down-regulated while proteasome subunit beta 4 and alpha 2 were up-regulated after CsA treatment. In summary, these data indicate down-regulation of synthetic processes and up-regulation of catabolic pathways.
Several enzymes controlling nucleobase/nucleoside/ nucleotide metabolism were also found altered by CsA. The decrease in uridin monophosphate synthetase, involved in the synthesis of pyrimidines, together with the up-regulation of s-methyl-5-thioadenosine phosphorylase and purine nucleotide phosphorylase enzymes, both participating in the savage pathway of purines, suggests that low-energy viability due to mitochondrial respiratory chain dysfunction might cause a drop in nucleotide concentration and raised activity of the less costly savage pathways.
Finally, we observed that proteins that protect from oxidative damage and stress belonging to the peroxiredoxin or HSP families became down-regulated under the conditions used in these experiments.
To further confirm these proteomic results, antibodies against randomly selected proteins were used for WB assays using control and CsA-treated PCT cell extracts. In three of four instances, which include αB-crystallin, NACA and CypA, results were consistent with the data obtained in the proteomic analysis, while RACK-1 did not seem to follow the same pattern. Two dimensional WB assays using anti-RACK-1-specific antibodies showed a complex pattern of expression consistent with post-translational modifications that could not be observed by 1D WB. RACK-1 isoforms seemed to be differently affected by CsA treatment, although the total amount of the protein did not appear to change. Likely, only one isoform of the protein was picked up and identified in the proteomic analysis, producing data apparently contradictory to 1D WB assay results. To support this concept, 2D WB assays were also performed using antibodies against αB-crystallin and CypA. As shown in Figure 5 , when there was a single spot or several spots followed the same pattern after treatment, as occurred for α-B-crystallin and CypA, respectively, proteomic results fit with those obtained after 1D and 2D WB assays. In conclusion, and from a technical point of view, 1D WB assays and differential proteomic analysis might not be in agreement if isoforms of the same protein become differentially affected by the treatment and only one is spotted for identification. From a functional viewpoint, it is obvious that proteomic analyses fail to reveal the complexity related to post-translational modifications that underlies in any system beyond simple alterations in protein expression levels.
Next, we attempted to observe the expression pattern of these proteins in kidneys of CsA-treated mice by 1D WB assays. While αB-crystallin, RACK-1 and NACA levels were similar to those found in cultured treated cells, CypA levels remained unchanged. Since CypA is expressed in any cell type, these results suggest that proximal tubule cells might be more sensitive than other cells in the kidney to the effects of CsA in relation to CypA levels. A further possible explanation is that, in total kidney extracts, CypA differences became masked by the contribution of other cell types.
In conclusion, we identified putative markers of CsAinduced toxicity in proximal tubule cells that shall be thoroughly studied in the future to determine how specific they are for CsA compared with other immunosuppressants and/or other forms of injury in proximal tubule cells. We will define their correlation with standard metrics used to define and monitor the progression of acute kidney injury, such as the insensitive and non-specific serum creatinine and blood urea nitrogen levels that change only after significant kidney injury. Some of the proteins found in this study might constitute sensitive, specific and reliable biomarkers for early diagnosis/prognosis of acute kidney injury in preclinical and clinical studies, permitting the development of high-throughput innovative technologies for rapid multiplexed detection of markers at the bedside.
